Gill Ravinder K, Pant Nitika, Saksena Seema, Singla Amika, Nazir Talat M, Vohwinkel Lisa, Turner Jerrold R, Goldstein Jay, Alrefai Waddah A, Dudeja Pradeep K
Research Assistant Professor, Univ. of Illinois at Chicago, Jesse Brown V. A. Medical Center, Medical Research Service (600/151 820 South Damen Ave., Chicago, IL 60612.
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G254-62. doi: 10.1152/ajpgi.00354.2007. Epub 2007 Nov 8.
The enteric serotonin transporter (SERT) plays a critical role in modulating serotonin availability and thus has been implicated in the pathogenesis of various intestinal disorders. To date, SERT expression and function in the human intestine have not been investigated. Current studies were designed to characterize the function, expression, distribution, and membrane localization of SERT in the native human intestine. Real-time PCR studies showed relatively higher SERT mRNA expression in the human small intestine compared with colon (ileum >> duodenum >> jejunum). Northern blot analysis revealed three mRNA hybridizing species encoding SERT (3.0, 4.9, and 6.8 kb) in the human ileum. Consistent with SERT mRNA expression, SERT immunostaining was mainly detected in the epithelial cells of human duodenal and ileal resected tissues. Notably, SERT expression was localized predominantly to the apical and intracellular compartments and was distributed throughout the crypt-villus axis. Immunoblotting studies detected a prominent protein band ( approximately 70 kDa) in the ileal apical plasma membrane vesicles (AMVs) isolated from mucosa obtained from organ-donor intestine. Functional studies showed that uptake of [(3)H]serotonin (150 nM) in human ileal AMVs was 1) significantly increased in the presence of both Na(+) and Cl(-); 2) inhibited ( approximately 50%) by the neuronal SERT inhibitor, fluoxetine (10 microM) and by unlabeled 5-HT; and 3) exhibited saturation kinetics indicating the presence of a carrier-mediated process. Our studies demonstrated differential expression of SERT across various regions of the human intestine and provide evidence for the existence of a functional SERT capable of removing intraluminal serotonin in human ileal epithelial cells.
肠道5-羟色胺转运体(SERT)在调节5-羟色胺的可利用性方面发挥着关键作用,因此与多种肠道疾病的发病机制有关。迄今为止,尚未对人肠道中SERT的表达和功能进行研究。目前的研究旨在表征SERT在天然人肠道中的功能、表达、分布和膜定位。实时PCR研究表明,与结肠相比,人小肠中SERT mRNA表达相对较高(回肠>>十二指肠>>空肠)。Northern印迹分析显示,人回肠中有三种编码SERT的mRNA杂交物种(3.0、4.9和6.8 kb)。与SERT mRNA表达一致,SERT免疫染色主要在人十二指肠和回肠切除组织的上皮细胞中检测到。值得注意的是,SERT表达主要定位于顶端和细胞内区室,并分布于整个隐窝-绒毛轴。免疫印迹研究在从器官捐献者肠道获得的粘膜中分离出的回肠顶端质膜囊泡(AMV)中检测到一条突出的蛋白带(约70 kDa)。功能研究表明,人回肠AMV中[³H]5-羟色胺(¹⁵⁰ nM)的摄取:1)在Na⁺和Cl⁻存在下显著增加;2)被神经元SERT抑制剂氟西汀(¹⁰ μM)和未标记的5-羟色胺抑制(约50%);3)表现出饱和动力学,表明存在载体介导的过程。我们的研究证明了SERT在人肠道不同区域的差异表达,并为在人回肠上皮细胞中存在能够清除肠腔内5-羟色胺的功能性SERT提供了证据。